Concepts (226)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiology | 15 | 2022 | 140 | 3.970 |
Why?
|
| Cardiovascular Diseases | 22 | 2022 | 940 | 3.420 |
Why?
|
| Consensus | 12 | 2022 | 211 | 1.850 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2022 | 212 | 1.810 |
Why?
|
| Research Report | 4 | 2020 | 35 | 1.670 |
Why?
|
| Anticholesteremic Agents | 7 | 2022 | 49 | 1.410 |
Why?
|
| Practice Guidelines as Topic | 6 | 2019 | 772 | 1.320 |
Why?
|
| Atherosclerosis | 9 | 2019 | 204 | 1.280 |
Why?
|
| Cholesterol, LDL | 8 | 2022 | 161 | 1.200 |
Why?
|
| American Heart Association | 7 | 2021 | 142 | 1.170 |
Why?
|
| Cholesterol | 3 | 2022 | 331 | 1.050 |
Why?
|
| Clinical Decision-Making | 5 | 2020 | 109 | 0.890 |
Why?
|
| Expert Testimony | 3 | 2020 | 47 | 0.880 |
Why?
|
| Lipoprotein(a) | 1 | 2022 | 9 | 0.860 |
Why?
|
| Risk Assessment | 13 | 2021 | 2007 | 0.860 |
Why?
|
| Advisory Committees | 2 | 2019 | 73 | 0.820 |
Why?
|
| Coronary Artery Disease | 9 | 2021 | 696 | 0.790 |
Why?
|
| Lipids | 3 | 2017 | 298 | 0.640 |
Why?
|
| United States | 22 | 2022 | 7367 | 0.600 |
Why?
|
| Calcinosis | 3 | 2016 | 241 | 0.590 |
Why?
|
| Blood Chemical Analysis | 1 | 2017 | 43 | 0.580 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2017 | 60 | 0.570 |
Why?
|
| Electronic Nicotine Delivery Systems | 2 | 2018 | 180 | 0.560 |
Why?
|
| Hypolipidemic Agents | 2 | 2016 | 82 | 0.550 |
Why?
|
| Dyslipidemias | 4 | 2019 | 98 | 0.550 |
Why?
|
| Gemfibrozil | 1 | 2016 | 4 | 0.540 |
Why?
|
| Lipoproteins | 1 | 2017 | 161 | 0.540 |
Why?
|
| Biomedical Research | 1 | 2019 | 310 | 0.520 |
Why?
|
| Radiation Dosage | 4 | 2018 | 419 | 0.500 |
Why?
|
| Humans | 53 | 2022 | 68618 | 0.500 |
Why?
|
| Cardiac Imaging Techniques | 3 | 2018 | 35 | 0.470 |
Why?
|
| Primary Prevention | 1 | 2015 | 115 | 0.460 |
Why?
|
| Smoking | 3 | 2018 | 1452 | 0.460 |
Why?
|
| Coronary Angiography | 5 | 2019 | 866 | 0.450 |
Why?
|
| Radiation Exposure | 3 | 2018 | 84 | 0.430 |
Why?
|
| Disease Management | 1 | 2014 | 248 | 0.420 |
Why?
|
| Healthy Lifestyle | 2 | 2021 | 21 | 0.390 |
Why?
|
| Risk Factors | 17 | 2022 | 5731 | 0.380 |
Why?
|
| Cardiomyopathies | 1 | 2012 | 167 | 0.370 |
Why?
|
| Ezetimibe | 3 | 2022 | 6 | 0.360 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2016 | 2324 | 0.350 |
Why?
|
| Hyperlipidemias | 3 | 2021 | 90 | 0.320 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2022 | 1085 | 0.320 |
Why?
|
| Calcium | 1 | 2012 | 929 | 0.310 |
Why?
|
| Serine Proteinase Inhibitors | 2 | 2019 | 48 | 0.310 |
Why?
|
| Health Behavior | 2 | 2021 | 458 | 0.300 |
Why?
|
| Health Promotion | 2 | 2021 | 407 | 0.300 |
Why?
|
| Motivation | 2 | 2021 | 561 | 0.300 |
Why?
|
| Metabolic Diseases | 2 | 2017 | 37 | 0.280 |
Why?
|
| Peripheral Arterial Disease | 2 | 2018 | 83 | 0.270 |
Why?
|
| Nutrition Surveys | 2 | 2018 | 208 | 0.270 |
Why?
|
| Vascular Calcification | 2 | 2017 | 131 | 0.240 |
Why?
|
| Computed Tomography Angiography | 2 | 2019 | 424 | 0.230 |
Why?
|
| Triglycerides | 2 | 2021 | 184 | 0.220 |
Why?
|
| Risk Reduction Behavior | 2 | 2021 | 174 | 0.220 |
Why?
|
| Evidence-Based Medicine | 5 | 2018 | 438 | 0.210 |
Why?
|
| Smoking Cessation | 4 | 2019 | 1034 | 0.200 |
Why?
|
| Hypertriglyceridemia | 1 | 2021 | 21 | 0.200 |
Why?
|
| Diet Therapy | 1 | 2021 | 22 | 0.200 |
Why?
|
| Nutrition Policy | 1 | 2021 | 44 | 0.190 |
Why?
|
| Statistics as Topic | 1 | 2021 | 219 | 0.190 |
Why?
|
| Education, Distance | 1 | 2021 | 34 | 0.190 |
Why?
|
| Congresses as Topic | 1 | 2021 | 85 | 0.180 |
Why?
|
| Biomarkers | 4 | 2019 | 1593 | 0.180 |
Why?
|
| Tobacco, Smokeless | 1 | 2020 | 40 | 0.180 |
Why?
|
| Education, Medical, Continuing | 1 | 2021 | 136 | 0.180 |
Why?
|
| Predictive Value of Tests | 6 | 2018 | 1465 | 0.170 |
Why?
|
| Preventive Medicine | 1 | 2019 | 48 | 0.170 |
Why?
|
| Lipoproteins, LDL | 1 | 2021 | 343 | 0.170 |
Why?
|
| Telemedicine | 2 | 2017 | 700 | 0.160 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 102 | 0.160 |
Why?
|
| Tobacco Use Cessation | 1 | 2018 | 44 | 0.160 |
Why?
|
| Drug Costs | 1 | 2019 | 87 | 0.160 |
Why?
|
| Physician's Role | 1 | 2018 | 116 | 0.150 |
Why?
|
| Amino Acids | 1 | 2018 | 131 | 0.150 |
Why?
|
| Occupational Exposure | 1 | 2018 | 122 | 0.150 |
Why?
|
| Medication Therapy Management | 1 | 2017 | 32 | 0.150 |
Why?
|
| Muscular Diseases | 1 | 2017 | 41 | 0.150 |
Why?
|
| Eligibility Determination | 1 | 2017 | 31 | 0.140 |
Why?
|
| Hypercholesterolemia | 1 | 2017 | 86 | 0.140 |
Why?
|
| Tin | 1 | 2016 | 16 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 504 | 0.140 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2016 | 12 | 0.140 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 286 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 170 | 0.130 |
Why?
|
| Coronary Vessels | 2 | 2017 | 313 | 0.130 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 158 | 0.130 |
Why?
|
| Drug Combinations | 1 | 2016 | 304 | 0.130 |
Why?
|
| Cancer Survivors | 1 | 2017 | 146 | 0.120 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 106 | 0.120 |
Why?
|
| Breast | 1 | 2015 | 137 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 511 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 378 | 0.120 |
Why?
|
| Muscle, Skeletal | 1 | 2017 | 396 | 0.120 |
Why?
|
| Morbidity | 1 | 2014 | 130 | 0.120 |
Why?
|
| Female | 17 | 2021 | 38074 | 0.120 |
Why?
|
| Middle Aged | 13 | 2021 | 21147 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 163 | 0.120 |
Why?
|
| Benchmarking | 3 | 2018 | 91 | 0.110 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 137 | 0.110 |
Why?
|
| Diet | 1 | 2017 | 514 | 0.110 |
Why?
|
| Diabetes Mellitus | 2 | 2017 | 694 | 0.110 |
Why?
|
| Prognosis | 2 | 2017 | 2093 | 0.110 |
Why?
|
| Myocardial Ischemia | 1 | 2014 | 172 | 0.110 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2013 | 45 | 0.110 |
Why?
|
| Mammography | 1 | 2015 | 310 | 0.100 |
Why?
|
| Patient Safety | 3 | 2018 | 202 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2015 | 403 | 0.100 |
Why?
|
| Aged | 10 | 2021 | 14862 | 0.100 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 1242 | 0.090 |
Why?
|
| Algorithms | 2 | 2017 | 1196 | 0.090 |
Why?
|
| Heart Ventricles | 1 | 2014 | 738 | 0.090 |
Why?
|
| Male | 13 | 2021 | 37321 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 2279 | 0.080 |
Why?
|
| Time Factors | 5 | 2018 | 4655 | 0.080 |
Why?
|
| Adult | 8 | 2021 | 21403 | 0.080 |
Why?
|
| Comorbidity | 3 | 2019 | 1426 | 0.080 |
Why?
|
| Treatment Outcome | 6 | 2019 | 7029 | 0.070 |
Why?
|
| Hypertension | 1 | 2017 | 1535 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 1536 | 0.070 |
Why?
|
| Arteritis | 1 | 1986 | 4 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2020 | 1046 | 0.070 |
Why?
|
| Adolescent | 4 | 2020 | 8912 | 0.070 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 191 | 0.070 |
Why?
|
| Guideline Adherence | 2 | 2018 | 287 | 0.060 |
Why?
|
| Retrospective Studies | 6 | 2019 | 7277 | 0.060 |
Why?
|
| South Carolina | 3 | 2019 | 2752 | 0.060 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1986 | 157 | 0.060 |
Why?
|
| Network Meta-Analysis | 1 | 2022 | 5 | 0.050 |
Why?
|
| Prevalence | 2 | 2019 | 1619 | 0.050 |
Why?
|
| Pregnancy | 2 | 2019 | 2334 | 0.050 |
Why?
|
| Patient Care Management | 1 | 2021 | 40 | 0.050 |
Why?
|
| Virtual Reality | 1 | 2021 | 13 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 307 | 0.050 |
Why?
|
| Committee Membership | 1 | 2020 | 1 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 1753 | 0.050 |
Why?
|
| Body Weight | 1 | 2022 | 554 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2020 | 73 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2019 | 127 | 0.040 |
Why?
|
| Proprotein Convertase 9 | 1 | 2019 | 14 | 0.040 |
Why?
|
| Certification | 1 | 2019 | 66 | 0.040 |
Why?
|
| Texas | 1 | 2019 | 92 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2019 | 248 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2018 | 33 | 0.040 |
Why?
|
| Models, Economic | 1 | 2019 | 69 | 0.040 |
Why?
|
| Fabaceae | 1 | 2018 | 12 | 0.040 |
Why?
|
| Dairy Products | 1 | 2018 | 13 | 0.040 |
Why?
|
| Dietary Sugars | 1 | 2018 | 7 | 0.040 |
Why?
|
| Alcoholic Beverages | 1 | 2018 | 18 | 0.040 |
Why?
|
| Professional Practice Gaps | 1 | 2018 | 1 | 0.040 |
Why?
|
| Diabetes, Gestational | 1 | 2019 | 81 | 0.040 |
Why?
|
| Communication | 1 | 2021 | 329 | 0.040 |
Why?
|
| Veterans Health | 1 | 2019 | 62 | 0.040 |
Why?
|
| Risk | 1 | 2019 | 563 | 0.040 |
Why?
|
| Education, Medical | 1 | 2019 | 147 | 0.040 |
Why?
|
| Sequestering Agents | 1 | 2017 | 1 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2017 | 26 | 0.040 |
Why?
|
| Ankle Brachial Index | 1 | 2017 | 10 | 0.040 |
Why?
|
| Ultrasonography, Doppler | 1 | 2017 | 57 | 0.040 |
Why?
|
| Pre-Eclampsia | 1 | 2019 | 202 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 136 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 182 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2017 | 86 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 504 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 135 | 0.030 |
Why?
|
| Text Messaging | 1 | 2017 | 47 | 0.030 |
Why?
|
| Cell Phone | 1 | 2017 | 44 | 0.030 |
Why?
|
| Polypharmacy | 1 | 2016 | 31 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 193 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2018 | 447 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 241 | 0.030 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2016 | 41 | 0.030 |
Why?
|
| Young Adult | 2 | 2019 | 5717 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2019 | 631 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 151 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2016 | 289 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 536 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2358 | 0.030 |
Why?
|
| Curriculum | 1 | 2019 | 575 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2017 | 307 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 186 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 848 | 0.030 |
Why?
|
| Registries | 1 | 2018 | 733 | 0.030 |
Why?
|
| Aortic Valve Insufficiency | 1 | 1994 | 47 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 1056 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 659 | 0.030 |
Why?
|
| Life Style | 1 | 2016 | 338 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 931 | 0.030 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2017 | 373 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 546 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 3259 | 0.030 |
Why?
|
| Inflammation | 1 | 2019 | 1030 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 689 | 0.030 |
Why?
|
| Heart Valve Prosthesis | 1 | 1994 | 222 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 880 | 0.030 |
Why?
|
| Aortic Valve Stenosis | 1 | 1994 | 177 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2013 | 249 | 0.030 |
Why?
|
| Obesity | 1 | 2019 | 1076 | 0.030 |
Why?
|
| Observer Variation | 1 | 2013 | 330 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 2800 | 0.030 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 1991 | 12 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1851 | 0.020 |
Why?
|
| Myocardial Infarction | 2 | 1988 | 807 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1420 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 1994 | 481 | 0.020 |
Why?
|
| Exercise | 1 | 2017 | 658 | 0.020 |
Why?
|
| Veterans | 1 | 2018 | 904 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1553 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2016 | 3705 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 4848 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 2077 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 1988 | 183 | 0.020 |
Why?
|
| Child | 1 | 2015 | 6405 | 0.010 |
Why?
|
| Coronary Artery Bypass | 2 | 1994 | 218 | 0.010 |
Why?
|
| Survival Analysis | 2 | 1994 | 714 | 0.010 |
Why?
|
| Stroke Volume | 2 | 1994 | 586 | 0.010 |
Why?
|
| Aortic Valve | 1 | 1994 | 249 | 0.010 |
Why?
|
| Coronary Disease | 1 | 1994 | 358 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1994 | 737 | 0.010 |
Why?
|
| Sex Factors | 1 | 1994 | 1266 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1988 | 258 | 0.000 |
Why?
|
| Age Factors | 1 | 1991 | 1864 | 0.000 |
Why?
|
| Random Allocation | 1 | 1988 | 442 | 0.000 |
Why?
|
| Heart Rate | 1 | 1988 | 568 | 0.000 |
Why?
|
| Patient Compliance | 1 | 1988 | 402 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1988 | 1451 | 0.000 |
Why?
|